Sustained good momentum, but with some caution

18/11/22 -"After another quarterly performance beat in Q3, Novo remains on track to sustain its exceptional operating momentum. Besides our medium-term estimates resetting marginally higher, the DCF and NAV ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

18/11/22

Download

You may also be interested by these reports :

25/08/25

PolyPeptide

Attractive return potential remains – Confidence slightly raised

22/08/25

Novonesis

Though missing expectations, Novonesis demonstrated strong momentum in H1 2025, achieving 9% organic growth and 8% in Q2, resulting in a narrowed ...

21/08/25

Siegfried

Guidance reaffirmed while FX and destocking mask momentum

20/08/25

Idea Kicker

Following Donald Trump’s tariff threats and given the generic/biosimilar medicine makers’ relatively thin profitability, the markets were quick to ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue

Novo Nordisk